Mirae Asset Capital
VC Fund
Mumbai, India
Mirae Asset Capital is a VC fund in Mumbai focused on Health Care and Biotechnology. South Korean investment firm, headquartered in Seoul.
- Total investments:
- 140
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Mirae Asset Capital invests in
Stages Mirae Asset Capital invests in
Countries Mirae Asset Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3M–$47M
- Series B
- $7.5M–$105M
- Series C
- $22M–$291M
Investment Focus
Industry
- Health Care 29 (21%)
- Biotechnology 27 (19%)
- Artificial Intelligence 21 (15%)
- Medical 18 (13%)
- Information Technology 16 (11%)
Stage
- Series B 36 (26%)
- Series A 33 (24%)
- Series C 19 (14%)
- Seed 17 (12%)
- Series D 10 (7%)
Country
- South Korea 64 (46%)
- United States 32 (23%)
- India 4 (3%)
- Australia 2 (1%)
- China 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Kang
Chief Investment Officer and Head Coverage at Mirae Asset Capital Markets
|
Chief Investment Officer and Head Coverage at Mirae Asset Capital Markets | Total investments: 0 | Find email | |
Hyeon-Joo Park
Founder and GISO
|
Founder and GISO | Total investments: 0 | Find email | |
Jinwoo Lee
Senior Manager
|
Senior Manager | Total investments: 2 | Find email | |
Jisang Yoo
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Soojung Kim
Manager
|
Manager | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flexell Space
|
Flexell Space engages in space solar cells, focusing on improving cost, delivery, design, and power efficiency. | $20M / Series A / Jul 14, 2026 | |
Linq
|
We are creating ‘hyper-automated insurance platforms’ to comprehensively support underwriters and claim adjusters and to facilitate communication between insurers and reinsurers using AI and deep learning. | $22M / Series A / Jul 02, 2026 | |
Asteromorph
|
Asteromorph is an artificial intelligence (AI) research startup for the development of scientific superintelligence | $31.3M / Seed / May 29, 2026 | |
Tynapse
|
Tynapse develops artificial intelligence security and governance software focused on monitoring and controlling AI agents in enterprise environments. The company provides a runtime trust layer that evaluates AI-generated outputs, tool usage, and automated actions in real time to identify risks such as hallucinations, prompt injection attacks, dataleakage, and unauthorized behavior. Its platform includes AI guardrails, compliance monitoring, audit logging, and explainability tools designed to support regulatory and operational oversight for AI systems. Tynapse also generates traceability records and trust attestation documentation that organizations can use for governance and compliance processes. The company’s technology integrates between enterprise applications and large language models to inspect requests, enforce policies, and manage sensitive data handling. Its solutions are used in sectors such as finance and enterprise software where AI systems require security controls, monitoring, and accountability mechanisms. | $3.2M / Seed / Apr 28, 2026 | |
FairSquare Labs
|
FairSquare Labs offers services for digital asset management and Web 3. Blockchain innovations like the security token mainnet, multi-signature and MPC wallets, de-fi, and dex were created by them. They also mine, stake, trade, and fund crypto venture capital initiatives as well. They believe that the strength of their team places us in a uniqueposition to bridge the gap between traditional and digital assets. | Series B / Apr 15, 2026 | |
Aim Intelligence
|
Aim Intelligence has developed 'AIM Red', a generative AI solution for automatic vulnerability detection and security diagnosis. AIM Red, a security performance evaluation solution for generative AI, automates attack prompt creation for enterprises' red teams. | $6.7M / Series A / Apr 10, 2026 | |
|
Mifeng Technology
|
Mifeng Technology provides an embodied intelligence data platform for AI and robotics applications. | Seed / Feb 13, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
Endorobotics
|
Endorobotics is an educational technology company specializing in exam preparation solutions. Its platform provides automated question generation, adaptive difficulty adjustment, CSAT-style question modeling, and the creation of similar questions based on incorrect answers. The company enables middle and high school educators and students to accesspersonalized mock examinations, enhance learning outcomes, and streamline exam preparation through automation and data-driven insights. | $22.2M / Series C / Dec 03, 2025 | |
AITRICS
|
AITRICS delivers AI-powered medical software designed to support clinicians in detecting and preventing critical patient deterioration. The company’s core product, AITRICS‑VC (VitalCare), continuously monitors data from electronic medical records (EMRs), including vital signs, lab tests, consciousness levels, and other relevant clinicalmeasurements to predict adverse events such as sepsis, cardiac arrest, unexpected ICU transfers, or mortality several hours before they occur.AITRICS-VC operates in real time, delivering risk scores and alerts to clinicians to enable earlier intervention and better resource allocation in hospital settings. The platform has been certified by the relevant regulatory authority in its home country and is classified as an “innovative medical device,” reflecting regulatory recognition of its predictive-analytics capabilities. In addition to monitoring and prediction, AITRICS engages in ongoing clinical validation and research; it publishes studies in peer-reviewed journals and presents its work in international AI conferences, indicating a commitment to evidence-based development and transparency in performance. | $23.8M / Series C / Dec 01, 2025 | |
| See all 140 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Mirae Asset Capital invest in?
Mirae Asset Capital invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 140 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mirae Asset Capital's check size?
Mirae Asset Capital typically joins rounds of $3M–$47M at Series A, $7.5M–$105M at Series B and $22M–$291M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mirae Asset Capital participates in.
How do I contact Mirae Asset Capital?
Public channels for Mirae Asset Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mirae Asset Capital?
The team at Mirae Asset Capital includes David Kang (Chief Investment Officer and Head Coverage at Mirae Asset Capital Markets), Hyeon-Joo Park (Founder and GISO) and Jinwoo Lee (Senior Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
